Cost-effective models for flutamide for prostate carcinoma patients are they helpful to policy makers?

Cancer

Volumn 77, Issue 9, 1996, Pages 1854-1861

  Bennett, Charles L ^a,b,c,h   Matchar, David ^d   McCrory, Doug ^d   McLeod, David G ^e   Crawford, E David ^f   Hillner, Bruce E ^g  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^f UNIVERSITY OF COLORADO HOSPITAL   (United States)

^g VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h Lakeside VA   (United States)

Author keywords

Combined androgen blockade; Cost effectiveness; Flutamide; Medicare; Metastatic prostate cancer

Indexed keywords

FLUTAMIDE;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HUMAN; MALE; MEDICARE; PRIORITY JOURNAL; PROSTATE CARCINOMA; QUALITY OF LIFE;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; CARCINOMA; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; FLUTAMIDE; FOCUS GROUPS; HEALTH CARE COSTS; HUMANS; MALE; META-ANALYSIS; MODELS, ECONOMIC; MULTICENTER STUDIES; NATIONAL INSTITUTES OF HEALTH (U.S.); ORCHIECTOMY; POLICY MAKING; PROSTATIC NEOPLASMS; QUALITY OF LIFE; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES; VALUE OF LIFE;

EID: 0029867410     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960501)77:9<1854::AID-CNCR15>3.0.CO;2-Z     Document Type: Article

References (26)

1. Weinstein M, Stason WB. Cost-effectiveness of interventions to prevent or treat coronary heart disease. Annu Rev Public Health 1985;6:41-63.
2. Welch HG, Valuing clinical strategies early in their development. Ann Intern Med 1992;116:253-4.
3. Gulati SC, Bennett CL. Granulocyte-macrophage colony stimulating factor as adjunct therapy in relapsed Hodgkin disease. Ann Intern Med 1992;116:177-82.
4. Drummond MF. Cost-effectiveness guidelines for reimbursement of pharmaceuticals: Is economic evaluation ready for its enhanced status? Health Econ 1992;1:85-92.
5. Drummond MF, Davies L. Economic analysis alongside clinical trials: Revisiting the methodologies issues. Int J Technol Assess Health Care 1991;7:561-3.
6. Hillman AL, Eisenberg JM, Pauly MV, Bloome BS, Glick K, Kinosian B, Schwartz JS. Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies. N Engl J Med 1991;324:1362-5.
7. Bennett CL, Hillner, BE, Smith TJ. Clinical Oncology, 1st Ed. New York: Churchill Livingstone, Inc., 1995:187-200.
8. Bennett CL, Armitage IL, Armitage GO, Schwartz CE, Bierman PJ, Vose JM, et al. Costs and outcome for autologous bone marrow transplantation at the University of Nebraska: 1987-1991. J Clin Oncol 1995;13:969-73.
9. Coyle D, Drummond M. Does expenditure on pharmaceuticals give good value for money? current evidence and policy implications. Health Policy 1993;26:55-75.
10. Wingo PA, Tong T, Bolden S. Cancer Statistics. CA - Cancer J 1995;45:8-31.
11. Gee WF, Holtgrewe HL, Albertson PC. Practice trends in the diagnosis and management of prostate cancer in the United States. J Urol 1995;154:207-8.
12. Crawford ED, Eisenberger MA, McLeod DG. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989;321:419-24.
13. Denis LJ, Whelan P, deMoura JL. Goserelin acetate and flutamide vs. orchiectomy: A phase III EORTC trial (30853). Urology 1993;42:119-30.
14. Denis L, Murphy GP. Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer. Cancer 1993;72(Suppl):3888-95.
15. Prostate Cancer Trialists' Overview Group. Maximum androgen blockade in advanced prostate cancer: An overview of 22 randomized trials with 3,283 deaths in 5,710 patients. Lancet 1995;346:265-9.
16. Hillner BE, McLeod DG, Crawford ED, Bennett CL. Estimating the cost-effectiveness of total androgen blockade with flutamide in M1 prostate cancer. Urology 1995;45:633-40.
17. Ferguson BM, Keown PA. An introduction to utility measurement in health care. Infect Control Hosp Epidemiol 1995;16:240-7.
18. Nord E. Methods for quality adjustment of life years. Soc Sci Med 1992;34:560-6.
19. Beck JR, Pauker SG. The Markov process in medical prognosis. Med Decision Making 1983;3:419-28.
20. Pauker SG, Kassierer JP. Decision analysis. N Engl J Med 1987;316:250-8.
21. Bennett CL, Smith TJ, George SL, Hillner BE, Fleishman S, Neill HB. Free-riding and the prisoner's dilemma: Problems in funding economic analyses of phase III clinical trials. J Clin Oncol 1995;13:969-73.
22. Bennett CL, McCrory DC, Matchar DB. Utility assessments for metastatic prostate cancer vary according to practice composition. Proc Am Soc Clin Oncol 1995;1650a.
23. Fleming C, Wasson J, Albertson P. A decision analysis of alternative strategies for clinically localized prostate cancer. JAMA 1993;269:2650-8.
24. Antman K. Reimbursement issues facing patients, providers, and payers. Cancer 1993;72(Suppl):2842-5.
25. Blustein J. Medicare coverage, supplemental health insurance, and the use of mammography by older women. N Engl J Med 1995;332:1138-43.
26. Kolasso M. In Discussion [study published May 1994 in J Pain Sympt Manag 1994;12: F-D-C-Reports, Chevy Chase, MD]. Agency for Health Care Policy and Research: Management of Cancer Pain. Clinical Practice Guideline, US Department of Health and Human Services, Public Health Services, 1994.